Real World Outcome of Atezolizumab in First Line Metastatic Urothelial Cancer in Cisplatin Ineligible Patients

Purpose: The management of metastatic urothelial cancer (mUC) is challenging. It is predominately a disease of the elderly population. The median age in the UK at which patients present with urothelial carcinoma is over 70 years. A large population of patients is unsuitable for cisplatin based therapy due to poor performance status and medical comorbidities. Overall outcome was poor due to limited treatment options. Recently, immune checkpoint inhibitors have improved disease response and survival.

Source: Clinical Oncology - March 31, 2020 Category: Radiology Authors: S. Abdullah, P. Das, L. Puttarchaiah, S. Benney, C. Wards Source Type: research